Active, not recruitingPhase 3NCT04211337
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
Studying Medullary thyroid carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Loxo Oncology, Inc.
- Principal Investigator
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PMEli Lilly and Company
- Intervention
- Selpercatinib(drug)
- Enrollment
- 291 target
- Eligibility
- 12 years · All sexes
- Timeline
- 2020 – 2027
Study locations (30)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- City of Hope National Medical Center, Duarte, California, United States
- UCLA Hematology/Oncology - Westwood (Building 100), Los Angeles, California, United States
- University of California Davis (UC Davis) Comprehensive Cancer Center, Sacramento, California, United States
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States
- Emory University, Atlanta, Georgia, United States
- University of Chicago Medical Center, Chicago, Illinois, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- University of Cincinnati Medical Center, Cincinnati, Ohio, United States
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
- University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
- Thomas Jefferson University, Philadelphia, Pennsylvania, United States
- University of Texas MD Anderson Cancer Center, Houston, Texas, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Eli Lilly and Company
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04211337 on ClinicalTrials.govOther trials for Medullary thyroid carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07383246CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTCCancer Institute and Hospital, Chinese Academy of Medical Sciences
- RECRUITINGNANCT07138716Research on the Application of 68Ga-DOTA-CCK-FS PET/CT in MTCLuo Yaping
- ENROLLING BY INVITATIONNCT06852144PET-TC in Thyroid EvaluationIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGNANCT06141369Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)Shanghai Jiao Tong University School of Medicine
- RECRUITINGNANCT0627718068Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTCCancer Institute and Hospital, Chinese Academy of Medical Sciences
- RECRUITINGPHASE1NCT06520319Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid CarcinomaFirst Affiliated Hospital of Fujian Medical University
- RECRUITINGPHASE4NCT05830500Study of Anlotinib in Patients With Advanced Medullary Thyroid CarcinomaChia Tai Tianqing Pharmaceutical Group Co., Ltd.
- ACTIVE NOT RECRUITINGPHASE1NCT04877613GFRα4 CAR T Cells in MTC PatientsUniversity of Pennsylvania